

Regd. & Corp. Office:  
1506, Chiranjiv Tower,  
43, Nehru Place,  
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),  
E-mail: info@medicamen.com  
Web: www.medicamen.com  
CIN No.: L74899DL1993PLC056594

Ref: STEX/OUTCOME/2023-24

Date: 29.05.2023

<b>BSE Limited</b> 25th Floor Phiroze Jeejebhoy Towers Dalal Street, Mumbai 400 001  <b>BSE Code-531146</b>	<b>National Stock Exchange of India Limited</b> Exchange Plaza, C-1, Block - G Bandra Kurla Complex Bandra (East) Mumbai - 400 051  <b>NSE Code: MEDICAMEQ</b>
--	--

**Sub. : Outcome of Board Meeting**

Dear Sir,

We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended on March 31, 2023.

Pursuant to Regulation 30 & 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- Statement showing the Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and year ended on March 31, 2023 as **Annexure-A** and
- Statutory Audit Report on the Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and year ended on March 31, 2023 as **Annexure-B**

Further Board of Directors at their meeting approved the following resolutions:

- Recommended a final dividend @ 10% on Equity Shares of Rs. 10/- each i.e. Re 1/- per Equity Share for the Financial Year 2022-23.
- Appointment of M/s SPB & Co., Cost Accountants as Cost Auditor of the Company for the financial year 2023-24.
- Appointment of M/s Cheena & Associates as Internal Auditor of the Company for the financial year 2023-24.
- Appointment of M/s AMJ & Associates, Company Secretaries as Secretarial Auditor of the Company for the financial year 2023-24.

Please note that the reports of Auditors are with unmodified opinion with respect to the Audited Financial Results of the Company for the quarter/financial year ended March 31, 2023.

Please also find enclosed herewith declaration as per Regulation 33(3)(d) of SEBI (LODR), 2015 in respect of Auditor's Report with un-modified opinion for the Audited Financial Results for the quarter and year ended 31st March 2023.

The meeting of the Board of Directors commenced on 02.30 p.m. and concluded at 04.00 p.m.



The Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and year ended on March 31, 2023, as approved by the Board, will also be available on the Company's website [www.medicamen.com](http://www.medicamen.com).

This is for your information and records.

Thanking You.

Yours faithfully,

**For Medicamen Biotech Limited**



**Parul Choudhary**  
**Company Secretary**  
**ACS44157**





Particulars	31.03.2023 Audited	31.12.2022 Un-audited	31.03.2022 Audited	31.03.2023 Audited	31.03.2022 Audited	31.12.2022 Un-audited	31.03.2022 Audited	31.03.2023 Audited	31.03.2023 Audited	31.03.2022 Audited
8 Other Comprehensive Income Item that will not reclassified to Profit & Loss	-	-	-	-	-	-	-	-	-	-
9 Total Comprehensive Income net of Tax	404.60	375.94	275.47	1,500.20	1,490.64	377.02	274.54	376.87	1,472.85	1,489.71
10 Net Profit/(Loss) attributable to a) Controlling Interest b) Non-Controlling Interest	-	-	-	-	-	376.48 0.54	-	388.97 -12.10	1,484.41 -11.56	-
11 Paid up equity share capital (Rs. 10/- per share)	1,265.11	1,265.11	1,221.66	1,265.11	1,221.66	1,265.11	1,221.66	1,265.11	1,265.11	1,221.66
12 Earning Per Share (Rs.) Basic	3.25	2.97	2.25	12.04	12.20	2.98	2.25	3.03	11.82	12.19
Diluted	3.25	2.97	2.25	12.04	12.20	2.98	2.25	3.03	11.82	12.19

**NOTES :**

- The above Audited standalone and consolidated financial results for the quarter and year ended March 31, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors of the company at its meeting held on 29th May 2023. The above results have been audited by the statutory auditors of the Company. The reports of the statutory auditors are unqualified.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules there under and in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated July 5, 2016 and other recognized accounting practices and policies to the extent applicable.
- The Board of Directors have recommended a final dividend @ 10% on Equity Shares of Rs. 10/- each i.e. Re 1/- per Equity Share subject to approval of the members of the company in ensuing Annual General Meeting.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - "Earning per Share"
- The other expenses and Employee benefits expenses includes Rs. 3.50 Crores approximately incurred during Financial Year 2022-23 on creating domestic marketing network for Oncology products.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.
- The figures of the last quarter ended March 31, 2023 and March 31, 2022 are the balancing figures between audited figures in respect to full financial year and the published unaudited year to date figure upto the period end of the third quarter of the relevant financial year, which were subject to limited review.

Place : New Delhi  
Dated : 29.05.2023

For & on behalf of Board of Directors  
Medicamen Biotech Limited



*R. Bishnoi*

(Rahul Bishnoi)  
Chairman

**MEDICAMEN BIOTECH LIMITED**

1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

**STANDALONE AND CONSOLIDATED ASSETS AND LIABILITIES AS AT 31.03.2023**

PARTICULARS	STANDALONE		CONSOLIDATED	
	31.03.2023 (Amount Rs. Lacs)	31.03.2022 (Amount Rs. Lacs)	31.03.2023 (Amount Rs. Lacs)	31.03.2022 (Amount Rs. Lacs)
<b>I. ASSETS</b>				
<b>Non-current assets</b>				
Property, plant and Equipment	9,146.60	9,211.75	9,175.88	9,211.75
Other Intangible Assets	89.77	35.98	89.77	35.98
Capital work-in-progress	-	-	-	-
<b>Financial Assets</b>				
Investments	407.65	206.14	-	-
Loans & Advance	108.94	86.52	110.66	86.52
Deferred Tax Assets (net)	186.52	49.64	187.95	49.64
Other non-current assets	1,941.85	881.69	1,951.20	881.69
<b>Total Non Current Assets</b>	<b>11,881.33</b>	<b>10,471.72</b>	<b>11,515.46</b>	<b>10,265.58</b>
<b>Current assets</b>				
Inventories	4,505.73	2,700.97	4,505.73	2,700.97
<b>Financial Assets</b>				
Trade Receivables	6,022.54	6,117.84	6,525.81	6,322.35
Cash and cash equivalents	2,044.29	381.49	2,077.88	382.48
Loans & Advance	690.35	526.38	692.59	526.38
Other Current Assets	2,534.00	2,371.59	2,534.26	2,371.59
<b>Total Current Assets</b>	<b>15,796.91</b>	<b>12,098.27</b>	<b>16,336.27</b>	<b>12,303.77</b>
<b>TOTAL ASSETS</b>	<b>27,678.24</b>	<b>22,569.99</b>	<b>27,851.73</b>	<b>22,569.35</b>
<b>II. EQUITY AND LIABILITIES</b>				
<b>Equity</b>				
Share Capital	1,265.11	1,221.66	1,265.11	1,221.66
Other Equity	18,114.49	13,582.12	18,076.30	13,425.31
<b>Total Equity</b>	<b>19,379.60</b>	<b>14,803.78</b>	<b>19,341.41</b>	<b>14,646.97</b>
<b>Non-current liabilities</b>				
<b>Financial Liabilities</b>				
Borrowings	86.96	507.36	86.96	507.36
Provisions	166.01	145.94	166.01	145.94
<b>Total Non Current Liabilities</b>	<b>252.97</b>	<b>653.30</b>	<b>252.97</b>	<b>653.30</b>
<b>Current Liabilities</b>				
<b>Financial Liabilities</b>				
Borrowings	2,331.31	1,927.50	2,331.31	1,927.50
Trade payables	4,554.54	4,173.83	4,758.59	4,330.00
Other Current liabilities	720.83	502.89	728.46	502.89
Provisions	69.03	82.31	69.03	82.31
Current tax liabilities (Net)	369.96	426.38	369.96	426.38
<b>Total Current Liabilities</b>	<b>8,045.67</b>	<b>7,112.91</b>	<b>8,257.35</b>	<b>7,269.08</b>
<b>TOTAL EQUITY &amp; LIABILITIES</b>	<b>27,678.24</b>	<b>22,569.99</b>	<b>27,851.73</b>	<b>22,569.35</b>

For and on behalf of the Board  
Medicamen Biotech Limited(Rahul Bishnoi)  
ChairmanPlace : New Delhi  
Date: 29.05.2023

**MEDICAMEN BIOTECH LIMITED**

1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

**STANDALONE AND CONSOLIDATED CASH FLOW STATEMENT FOR THE PERIOD 01.04.2022 TO 31.03.2023**

(All Fig. in Rs. Lacs)

Particulars	STANDALONE		CONSOLIDATED	
	2022-23 (Amount Rs. Lacs)	2021-22 (Amount Rs. Lacs)	2022-23 (Amount Rs. Lacs)	2021-22 (Amount Rs. Lacs)
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>				
Net Profit/(Loss) after tax from continuing operations	1,500.20	1,490.64	1,472.85	1,489.71
Non-cash adjustment to reconcile profit before tax to net cash flows				
Provision for Taxation	369.96	397.69	369.96	397.69
Adjustment for Deferred Tax	-136.88	-77.98	-138.31	-77.98
Financial Charges	292.27	140.06	292.27	140.06
Loss/(profit) on sale of fixed assets	-0.68	-0.12	-0.68	-0.12
Depreciation/amortization on continuing operation	635.35	577.14	636.66	577.14
Interest income	-72.07	-13.54	-72.07	-13.54
<b>Operating profit before working capital changes</b>	<b>2,588.15</b>	<b>2,513.89</b>	<b>2,560.68</b>	<b>2,512.96</b>
<b>Movement of working capital</b>				
Increase/(decrease) in trade payables	380.72	1,216.19	428.59	1,108.86
Increase / (decrease) in long-term provisions	20.07	30.39	20.07	30.39
Increase / (decrease) in short-term provisions	-439.66	-366.54	-439.66	-411.98
Increase/(decrease) in other current liabilities	217.94	3.78	225.57	12.49
Decrease/(increase) in trade receivables	95.30	-1,142.50	-203.46	-1,067.61
Decrease/(increase) in inventories	-1,804.76	-2,180.57	-1,804.76	-2,180.59
Decrease / (increase) in long-term loans and advances	-22.42	-8.98	-24.14	-8.98
Decrease / (increase) in short-term loans and advances	-163.97	187.57	-166.21	507.57
Decrease/(increase) in other current assets	149.93	673.53	149.67	353.53
Decrease/(increase) in other Non-current assets	-1,060.14	-125.73	-1,063.29	-125.73
Direct taxes paid	-312.34	-320.00	-312.34	-320.00
<b>Net cash flow from/ (used in) operating activities (A)</b>	<b>-351.18</b>	<b>481.03</b>	<b>-629.28</b>	<b>410.91</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>				
Purchase of fixed assets including intangible & CWIP	-623.31	-860.82	-660.11	-860.82
Purchase of non-current investments	-201.51	-	-	-
Interest received	72.07	13.54	72.07	13.54
<b>Net cash flow from/(used in) investing activities (B)</b>	<b>-752.75</b>	<b>-847.28</b>	<b>-588.04</b>	<b>-847.28</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES :</b>				
Proceeds from issuance of share capital	43.45	-	43.45	-
Proceeds from Securities Premium	3,037.16	-	3,037.16	-
Shares Warrants / Share Application Money	112.55	-	260.55	-
Capital Reserve	-	-	-2.00	-9.52
Long-term borrowings net of repayment / Repayment	-420.40	-133.10	-420.40	-133.10
Proceeds from short-term borrowings	403.81	834.63	403.81	834.64
Interest paid	-292.27	-140.06	-292.27	-140.06
Dividends paid on equity shares	-126.51	-122.17	-126.51	-122.17
Income Tax Provision Reverse for earlier year	50.34	-	50.34	-
Preferential issue Expenditure	-41.40	-	-41.40	-
<b>Net cash flow from/(used in) in financing activities (C)</b>	<b>2,766.73</b>	<b>439.30</b>	<b>2,912.73</b>	<b>429.79</b>
Net increase/(decrease) in cash and cash equivalents (A + B + C)	1,662.80	73.05	1,695.40	-6.58
Cash and cash equivalents at the beginning of the year	381.49	308.44	382.48	389.06
<b>Cash and cash equivalents at the end of the year</b>	<b>2,044.29</b>	<b>381.49</b>	<b>2,077.88</b>	<b>382.48</b>

For and on behalf of the Board  
Medicamen Biotech Limited(Rahul Bishnoi)  
ChairmanPlace : New Delhi  
Date: 29.05.2023

**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE  
FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS****TO THE BOARD OF DIRECTORS OF MEDICAMEN BIOTECH LIMITED****Report on the audit of the Standalone Financial Results****Opinion**

We have audited the accompanying statement of quarterly and year to date financial results of Medicamen Biotech Limited (the "Company") for the quarter ended March 31, 2023 and for the year ended March 31, 2023 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulation").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i) is presented in accordance with the requirements of the Listing Regulations in this regard; and
- ii) gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2023.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

**Management's Responsibilities for the Financial Results**

The Statement has been prepared on the basis of the annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the applicable accounting